The Immutep Ltd (ASX: IMM) share price is currently halted on Monday. This comes after the biotech company requested a trading halt from the ASX late last week.
Before being placed on ice, shares in the cancer immunotherapy developer finished Friday’s session up 3.95% to 39.5 cents.
Despite that gain, the stock has had a softer start to the year and remains around 5% lower in 2026.
Let’s take a look at what is happening with this ASX healthcare share.
Image source: Getty Images
Trading halt ahead of important clinical update
According to the release, Immutep requested that its shares be paused while it prepares to release a significant update to the market.
The pause relates to an upcoming update on the company’s Phase III TACTI…
